Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.23. On average, analysts expect Adial Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Adial Pharmaceuticals Stock Performance
NASDAQ:ADIL opened at $0.61 on Monday. The company has a market capitalization of $4.01 million, a PE ratio of -0.18 and a beta of 1.21. The company has a 50 day simple moving average of $0.70 and a two-hundred day simple moving average of $0.88. Adial Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $3.00.
Adial Pharmaceuticals Company Profile
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Read More
- Five stocks we like better than Adial Pharmaceuticals
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Constellation Powers Up With Reinforced AI Data Center Strategy
- What is the Australian Securities Exchange (ASX)
- Top Analyst-Rated Healthcare Stocks to Watch Now
- How to Find Undervalued Stocks
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
